RxDoctor Payments Data

Saad Kanaan, MD

Neurology · Dayton, OHNPI 1841502069

Payments from drug & device makers

$84,414in general payments, 2019–2025

Across 234 payments — averaging $360.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$65K
  • Biohaven Pharmaceuticals, Inc.$13K
  • Biohaven Pharmaceutical Holding Company Ltd.$5K
  • EMD Serono, Inc.$444
  • Supernus Pharmaceuticals, Inc.$319
  • Biogen$235
  • plus $651 from 12 others

What the payments were for

  • Speaking & faculty fees$77,72592%
  • Travel & lodging$2,7493%
  • Food & beverage$3,9415%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$84,414 in reported general payments places this provider in the 80th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$147,922
Medicare patients
125
Services billed
17,150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate107$112,605
Emgality PenGalcanezumab-Gnlm125$91,429
QuliptaAtogepant57$73,385
UbrelvyUbrogepant52$55,468
Ajovy AutoinjectorFremanezumab-Vfrm17$13,969
Sumatriptan Succinate88$1,573
RizatriptanRizatriptan Benzoate68$1,334
Gabapentin66$755
Naratriptan Hcl19$415
Topiramate81$413
Duloxetine Hcl39$398
Nortriptyline Hcl37$263
Amitriptyline Hcl13$209
Memantine Hcl16$129
Escitalopram Oxalate30$101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$64,889$128,853109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 702 neurology providers in Ohio.

Other neurology in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →